Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Price Performance

Shares of Achieve Life Sciences stock traded down $0.06 during trading on Friday, hitting $2.55. The stock had a trading volume of 401,123 shares, compared to its average volume of 1,185,432. The company has a debt-to-equity ratio of 0.85, a current ratio of 3.51 and a quick ratio of 3.51. The firm has a market cap of $88.46 million, a P/E ratio of -1.90 and a beta of 1.30. The business has a fifty day moving average of $2.98 and a two-hundred day moving average of $2.86. Achieve Life Sciences has a fifty-two week low of $1.84 and a fifty-two week high of $5.31.

Institutional Trading of Achieve Life Sciences

An institutional investor recently bought a new position in Achieve Life Sciences stock. AQR Capital Management LLC bought a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,802 shares of the biopharmaceutical company's stock, valued at approximately $32,000. Institutional investors own 33.52% of the company's stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.